VYNE Therapeutics Statistics
Share Statistics
VYNE Therapeutics has 16.66M
shares outstanding. The number of shares has increased by 4.69%
in one year.
| Shares Outstanding | 16.66M |
| Shares Change (YoY) | 4.69% |
| Shares Change (QoQ) | 3.11% |
| Owned by Institutions (%) | 0.09% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,198 |
| FTD / Avg. Volume | 1.17% |
Short Selling Information
The latest short interest is 217.47K, so 1.47% of the outstanding
shares have been sold short.
| Short Interest | 217.47K |
| Short % of Shares Out | 1.47% |
| Short % of Float | 1.49% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -3.58 and the forward
PE ratio is -1.37.
VYNE Therapeutics's PEG ratio is
0.05.
| PE Ratio | -3.58 |
| Forward PE | -1.37 |
| PS Ratio | 284.78 |
| Forward PS | 1.2 |
| PB Ratio | 2.74 |
| P/FCF Ratio | -4.19 |
| PEG Ratio | 0.05 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for VYNE Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.35,
with a Debt / Equity ratio of 0.
| Current Ratio | 4.35 |
| Quick Ratio | 4.35 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $38,538.46 |
| Profits Per Employee | $-3,064,153.85 |
| Employee Count | 13 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 4K |
| Effective Tax Rate | -0.01% |
Stock Price Statistics
The stock price has increased by -62.36% in the
last 52 weeks. The beta is 1.77, so VYNE Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.77 |
| 52-Week Price Change | -62.36% |
| 50-Day Moving Average | 1.54 |
| 200-Day Moving Average | 2.2 |
| Relative Strength Index (RSI) | 25.1 |
| Average Volume (20 Days) | 188,630 |
Income Statement
In the last 12 months, VYNE Therapeutics had revenue of 501K
and earned -39.83M
in profits. Earnings per share was -0.93.
| Revenue | 501K |
| Gross Profit | 497K |
| Operating Income | -43.64M |
| Net Income | -39.83M |
| EBITDA | -43.63M |
| EBIT | -43.64M |
| Earnings Per Share (EPS) | -0.93 |
Full Income StatementBalance Sheet
The company has 19.93M in cash and 99K in
debt, giving a net cash position of 19.83M.
| Cash & Cash Equivalents | 19.93M |
| Total Debt | 99K |
| Net Cash | 19.83M |
| Retained Earnings | -731.17M |
| Total Assets | 56.42M |
| Working Capital | 42.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -33.97M
and capital expenditures -117K, giving a free cash flow of -34.09M.
| Operating Cash Flow | -33.97M |
| Capital Expenditures | -117K |
| Free Cash Flow | -34.09M |
| FCF Per Share | -0.8 |
Full Cash Flow StatementMargins
Gross margin is 99.2%, with operating and profit margins of -8709.98% and -7950.9%.
| Gross Margin | 99.2% |
| Operating Margin | -8709.98% |
| Pretax Margin | -7944.71% |
| Profit Margin | -7950.9% |
| EBITDA Margin | -8709.18% |
| EBIT Margin | -8709.98% |
| FCF Margin | -6804.19% |
